{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007143","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.557161+00:00","generated_at":"2026-06-26T00:45:26.837899+00:00","sec_items":["1.01","1.02","2.03","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Treace Medical closes $54M draw on $150M MidCap debt facility; refinances $30M CRG loan","bullets":["$150M total facility ($120M term + $30M revolver) with MidCap; $54M drawn at closing.","Proceeds used to refinance existing $30M CRG term loan and replace $10M SVB revolver.","Interest: Adjusted Term SOFR (floor 1%, cap 3%) + 6% (term) or 4% (revolver); 48-month interest-only.","Liquidity now ~$220M including undrawn revolver; no min revenue covenant if liquidity > outstanding term loan.","CEO John Treace says financing provides capital-efficient vehicle to invest in growth."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007143","json":"https://secwatch.observer/filing/0000950170-22-007143.json","markdown":"https://secwatch.observer/filing/0000950170-22-007143.md","text":"https://secwatch.observer/filing/0000950170-22-007143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017022007143/0000950170-22-007143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017022007143/tmci-20220429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:45:26.837899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}